OKN-007

· Oblato, Inc

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for OKN-007, covering 2024-11-08 to 2025-12-10. Get the full timeline:

Most recent: Clinical Trial Update: OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma [Phase 1]